Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025
Vivoryon Therapeutics, a clinical stage company specializing in small molecule medicines development, has announced it will release its full year 2024 financial results and provide a corporate update on April 29, 2025.
The company will host a conference call and webcast at 3:00 pm CEST / 9:00 am EDT on the same day. The financial report will be accessible on Vivoryon's website, and participants can join the conference call through pre-registration on the provided link.
Vivoryon Therapeutics, un'azienda in fase clinica specializzata nello sviluppo di farmaci a piccole molecole, ha annunciato che pubblicherà i suoi risultati finanziari completi per l'anno 2024 e fornirà un aggiornamento aziendale il 29 aprile 2025.
La società terrà una conference call e una webcast alle 15:00 CEST / 9:00 EDT nello stesso giorno. Il rapporto finanziario sarà disponibile sul sito web di Vivoryon, e i partecipanti potranno accedere alla conference call tramite preregistrazione al link fornito.
Vivoryon Therapeutics, una compañía en fase clínica especializada en el desarrollo de medicamentos de moléculas pequeñas, ha anunciado que publicará sus resultados financieros completos del año 2024 y ofrecerá una actualización corporativa el 29 de abril de 2025.
La empresa realizará una llamada conferencia y una transmisión web a las 3:00 pm CEST / 9:00 am EDT el mismo día. El informe financiero estará disponible en el sitio web de Vivoryon, y los participantes podrán unirse a la llamada previa inscripción a través del enlace proporcionado.
Vivoryon Therapeutics는 소분자 의약품 개발을 전문으로 하는 임상 단계 기업으로, 2024년 전체 재무 결과를 발표하고 2025년 4월 29일에 기업 업데이트를 제공할 예정이라고 발표했습니다.
회사는 같은 날 오후 3시 CEST / 오전 9시 EDT에 컨퍼런스 콜과 웹캐스트를 진행합니다. 재무 보고서는 Vivoryon 웹사이트에서 확인할 수 있으며, 참가자는 제공된 링크를 통해 사전 등록 후 컨퍼런스 콜에 참여할 수 있습니다.
Vivoryon Therapeutics, une entreprise en phase clinique spécialisée dans le développement de médicaments à petites molécules, a annoncé qu'elle publiera ses résultats financiers complets pour l'année 2024 et fournira une mise à jour d'entreprise le 29 avril 2025.
L'entreprise organisera une conférence téléphonique et une diffusion en direct à 15h00 CEST / 9h00 EDT le même jour. Le rapport financier sera accessible sur le site web de Vivoryon, et les participants pourront rejoindre la conférence téléphonique via une préinscription sur le lien fourni.
Vivoryon Therapeutics, ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Arzneimitteln mit kleinen Molekülen spezialisiert hat, hat angekündigt, seine vollständigen Finanzergebnisse für das Jahr 2024 zu veröffentlichen und am 29. April 2025 ein Unternehmensupdate zu geben.
Das Unternehmen wird am selben Tag um 15:00 Uhr MESZ / 9:00 Uhr EDT eine Telefonkonferenz und eine Webcast veranstalten. Der Finanzbericht wird auf der Website von Vivoryon zugänglich sein, und Teilnehmer können über eine vorherige Registrierung über den bereitgestellten Link an der Telefonkonferenz teilnehmen.
- None.
- None.
Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025
Halle (Saale) / Munich, Germany, April 17, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its financial results for the full year 2024 and provide a corporate update on Tuesday, April 29, 2025. The Company will host a conference call and webcast open to the public. The report will be available for download on the Company's website (https://www.vivoryon.com/financial-information/).
Conference call details
Date: April 29, 2025
Time: 3:00 pm CEST / 9:00 am EDT
The conference call will be available via phone and webcast.
The live audio webcast of the call will be available on Vivoryon´s website at: https://www.vivoryon.com/news-and-events/presentations-webcasts/
To join the conference call via phone, participants may pre-register and will receive dedicated dial-in details to easily and quickly access the call via the following website:
https://register-conf.media-server.com/register/BI2bda60f4f9a245db834bc976d4d9ddd9
It is suggested participants dial into the conference call 15 minutes prior to the scheduled start time to avoid any delays in attendance.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by its passion for ground-breaking science and innovation, the Company strives to change the lives of patients in need suffering from severe diseases. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The Company has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer’s disease, inflammatory and fibrotic disorders, including of the kidney, and cancer. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu
Attachment
FAQ
When will Vivoryon Therapeutics (VVY) release its 2024 annual financial results?
What time is Vivoryon's (VVY) 2024 earnings call scheduled for?
How can investors access Vivoryon's (VVY) 2024 annual financial report?
Where can I join Vivoryon's (VVY) 2024 earnings conference call?
